 |
南京科佰生物科技有限公司
主營產品： atcc代理,ATCC細胞系,ATCC細胞株,ATCC細胞庫購買 |
11
聯(lián)系電話
|
南京科佰生物科技有限公司
主營產品： atcc代理,ATCC細胞系,ATCC細胞株,ATCC細胞庫購買 |
聯(lián)系電話
| 參考價 | 面議 |
更新時間：2022-08-01 09:25:25瀏覽次數(shù)：724
聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息，謝謝!
| 供貨周期 | 現(xiàn)貨 | 規(guī)格 | T-25 Flask |
|---|---|---|---|
| 貨號 | CBP74151 | 應用領域 | 生物產業(yè) |
| 主要用途 | 僅限科研使用 |
| CBP74151 | |
| I. Background | |
The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes. B7-1, also known as CD80, is a membrane receptor found in activated antigen presenting cells (APC). B7-2 (CD86) signaling through CTLA4 (CD152) has been shown to inhibit T- cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host’s immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer. | |
| II. Introduction | |
| Expressed gene: | PD-1、CD80、CD86 |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1ug/ml puromycin+800ug/ml hygromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| III. Representative Data | |
Figure 1. Dose Response of Blocking Antibodies in PD-1/CTLA4 Dual Effector Reporter Cells (C16) With PD-L1/CD80&CD86 aAPC Cells. | |
| |
